Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia

Ching Hon Pui, Deqing Pei, John T. Sandlund, Dario Campana, Raul C. Ribeiro, Bassem I. Razzouk, Jeffrey E. Rubnitz, Scott Howard, Nobuko Hijiya, Sima Jeha, Cheng Cheng, James R. Downing, William E. Evans, Mary V. Relling, Melissa Hudson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999. Our goal was to use the information to further refine therapy and advance cure rates. Methods: Cumulative incidence functions of any post-treatment failure or any post-treatment relapse were estimated by the method of Kalbfleisch and Prentice and compared with Gray's test. The Cox proportional hazards model was used to identify independent prognostic factors. Results: Of the 827 patients who completed all treatment while in initial complete remission, 134 patients subsequently had major adverse events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission. The cumulative incidence of any adverse event was 14.0% ± 1.2% (SE) at 5 years and 16.9% ± 1.4% at 10 years. The risk of any leukemic relapse was 10.0% ± 1.1% at 5 years and 11.4% ± 1.2% at 10 years. Male sex was the only independent predictor of relapse (hazard ratio, 1.74; 95% CI, 1.11 to 2.74; P = .02). Conclusion: Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate, but also to reduce the risk of development of second malignancies.

Original languageEnglish (US)
Pages (from-to)7936-7941
Number of pages6
JournalJournal of Clinical Oncology
Volume23
Issue number31
DOIs
StatePublished - Dec 1 2005

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Second Primary Neoplasms
Therapeutics
Incidence
Clinical Protocols
Treatment Failure
Proportional Hazards Models

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Pui, C. H., Pei, D., Sandlund, J. T., Campana, D., Ribeiro, R. C., Razzouk, B. I., ... Hudson, M. (2005). Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23(31), 7936-7941. https://doi.org/10.1200/JCO.2004.01.0033

Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. / Pui, Ching Hon; Pei, Deqing; Sandlund, John T.; Campana, Dario; Ribeiro, Raul C.; Razzouk, Bassem I.; Rubnitz, Jeffrey E.; Howard, Scott; Hijiya, Nobuko; Jeha, Sima; Cheng, Cheng; Downing, James R.; Evans, William E.; Relling, Mary V.; Hudson, Melissa.

In: Journal of Clinical Oncology, Vol. 23, No. 31, 01.12.2005, p. 7936-7941.

Research output: Contribution to journalArticle

Pui, CH, Pei, D, Sandlund, JT, Campana, D, Ribeiro, RC, Razzouk, BI, Rubnitz, JE, Howard, S, Hijiya, N, Jeha, S, Cheng, C, Downing, JR, Evans, WE, Relling, MV & Hudson, M 2005, 'Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia', Journal of Clinical Oncology, vol. 23, no. 31, pp. 7936-7941. https://doi.org/10.1200/JCO.2004.01.0033
Pui, Ching Hon ; Pei, Deqing ; Sandlund, John T. ; Campana, Dario ; Ribeiro, Raul C. ; Razzouk, Bassem I. ; Rubnitz, Jeffrey E. ; Howard, Scott ; Hijiya, Nobuko ; Jeha, Sima ; Cheng, Cheng ; Downing, James R. ; Evans, William E. ; Relling, Mary V. ; Hudson, Melissa. / Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 31. pp. 7936-7941.
@article{80093cb141574061afe8bdca2ecf405e,
title = "Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia",
abstract = "Purpose: We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999. Our goal was to use the information to further refine therapy and advance cure rates. Methods: Cumulative incidence functions of any post-treatment failure or any post-treatment relapse were estimated by the method of Kalbfleisch and Prentice and compared with Gray's test. The Cox proportional hazards model was used to identify independent prognostic factors. Results: Of the 827 patients who completed all treatment while in initial complete remission, 134 patients subsequently had major adverse events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission. The cumulative incidence of any adverse event was 14.0{\%} ± 1.2{\%} (SE) at 5 years and 16.9{\%} ± 1.4{\%} at 10 years. The risk of any leukemic relapse was 10.0{\%} ± 1.1{\%} at 5 years and 11.4{\%} ± 1.2{\%} at 10 years. Male sex was the only independent predictor of relapse (hazard ratio, 1.74; 95{\%} CI, 1.11 to 2.74; P = .02). Conclusion: Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate, but also to reduce the risk of development of second malignancies.",
author = "Pui, {Ching Hon} and Deqing Pei and Sandlund, {John T.} and Dario Campana and Ribeiro, {Raul C.} and Razzouk, {Bassem I.} and Rubnitz, {Jeffrey E.} and Scott Howard and Nobuko Hijiya and Sima Jeha and Cheng Cheng and Downing, {James R.} and Evans, {William E.} and Relling, {Mary V.} and Melissa Hudson",
year = "2005",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.01.0033",
language = "English (US)",
volume = "23",
pages = "7936--7941",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia

AU - Pui, Ching Hon

AU - Pei, Deqing

AU - Sandlund, John T.

AU - Campana, Dario

AU - Ribeiro, Raul C.

AU - Razzouk, Bassem I.

AU - Rubnitz, Jeffrey E.

AU - Howard, Scott

AU - Hijiya, Nobuko

AU - Jeha, Sima

AU - Cheng, Cheng

AU - Downing, James R.

AU - Evans, William E.

AU - Relling, Mary V.

AU - Hudson, Melissa

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose: We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999. Our goal was to use the information to further refine therapy and advance cure rates. Methods: Cumulative incidence functions of any post-treatment failure or any post-treatment relapse were estimated by the method of Kalbfleisch and Prentice and compared with Gray's test. The Cox proportional hazards model was used to identify independent prognostic factors. Results: Of the 827 patients who completed all treatment while in initial complete remission, 134 patients subsequently had major adverse events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission. The cumulative incidence of any adverse event was 14.0% ± 1.2% (SE) at 5 years and 16.9% ± 1.4% at 10 years. The risk of any leukemic relapse was 10.0% ± 1.1% at 5 years and 11.4% ± 1.2% at 10 years. Male sex was the only independent predictor of relapse (hazard ratio, 1.74; 95% CI, 1.11 to 2.74; P = .02). Conclusion: Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate, but also to reduce the risk of development of second malignancies.

AB - Purpose: We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999. Our goal was to use the information to further refine therapy and advance cure rates. Methods: Cumulative incidence functions of any post-treatment failure or any post-treatment relapse were estimated by the method of Kalbfleisch and Prentice and compared with Gray's test. The Cox proportional hazards model was used to identify independent prognostic factors. Results: Of the 827 patients who completed all treatment while in initial complete remission, 134 patients subsequently had major adverse events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission. The cumulative incidence of any adverse event was 14.0% ± 1.2% (SE) at 5 years and 16.9% ± 1.4% at 10 years. The risk of any leukemic relapse was 10.0% ± 1.1% at 5 years and 11.4% ± 1.2% at 10 years. Male sex was the only independent predictor of relapse (hazard ratio, 1.74; 95% CI, 1.11 to 2.74; P = .02). Conclusion: Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate, but also to reduce the risk of development of second malignancies.

UR - http://www.scopus.com/inward/record.url?scp=32944481786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944481786&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.01.0033

DO - 10.1200/JCO.2004.01.0033

M3 - Article

VL - 23

SP - 7936

EP - 7941

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -